Salts and solid form of a BTK inhibitor
First Claim
1. A method of treating at least one inflammatory and/or autoimmune disease selected from thrombotic thrombocytopenic purpura, polyarteritis nodosa, cutaneous lupus, cutaneous form of systemic sclerosis (CREST), mixed connective tissue disease, cryoglobulinemia, primary biliary sclerosis, sclerosing cholangitis, Al urticaria, IgA nephropathy, lupus nephritis, granulomatosis with polyangiitis, and pemphigus vulgaris in a mammal, comprising administering to said mammal a pharmaceutical composition comprising:
- at least one compound selected from (E) isomer, (Z) isomer, and a mixture of (E) and (Z) isomers of 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile; and
/orat least one pharmaceutically acceptable salt of any of the foregoing compounds; and
at least one pharmaceutically acceptable carrier or excipient.
3 Assignments
0 Petitions
Accused Products
Abstract
Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
57 Citations
10 Claims
-
1. A method of treating at least one inflammatory and/or autoimmune disease selected from thrombotic thrombocytopenic purpura, polyarteritis nodosa, cutaneous lupus, cutaneous form of systemic sclerosis (CREST), mixed connective tissue disease, cryoglobulinemia, primary biliary sclerosis, sclerosing cholangitis, Al urticaria, IgA nephropathy, lupus nephritis, granulomatosis with polyangiitis, and pemphigus vulgaris in a mammal, comprising administering to said mammal a pharmaceutical composition comprising:
-
at least one compound selected from (E) isomer, (Z) isomer, and a mixture of (E) and (Z) isomers of 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile; and
/orat least one pharmaceutically acceptable salt of any of the foregoing compounds; and at least one pharmaceutically acceptable carrier or excipient. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
Specification